Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab

Annals of Oncology

Volumn 22, Issue 4, 2011, Pages 990-991

  Goutagny, S ^a,b,c   Raymond, E ^a,c   Sterkers, O ^a,c   Colombani, J M ^a   Kalamarides, M ^a,b,c  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ABSENCE OF SIDE EFFECTS; ACOUSTIC NEURINOMA; ADULT; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFICACY; FEMALE; HEARING IMPAIRMENT; HUMAN; LETTER; MENINGIOMA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 79953323848     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr012     Document Type: Letter

References (5)

1. Plotkin SR, Stemmer-Rachamimov AO, Barker FG et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009; 61: 58-67.
2. Mautner VF, Nguyen R, Kutta H et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 2010; 12: 14-18.
3. Puchner MJA, Hans VH, Harati A et al. Bevacizumab-induced regression of anaplastic meningioma. Ann Oncol 2010; 21: 2445-2446.
4. Mautner VF, Nguyen R, Knecht R, Bokemeyer C. Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol 2010; 21: 2294-2295.
5. Panagopoulos AT, Lancellotti CLP, Veiga JCE et al. Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign atypical and anaplastic meningiomas. J Neurooncol 2008; 89: 73-87.